GlassScriptPhysician profile
Jennifer Lynne Stanley
NPI 1972560852
$870.78
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $33.16 · 2021: $2.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $183.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $157.52 | 2019-2020 | |
| Alkermes, INC. | $140.18 | 2019 | |
| Vanda Pharmaceuticals INC. | $118.74 | 2019 | |
| Indivior INC. | $62.23 | 2019 | |
| Allergan, INC. | $52.22 | 2019 | |
| Neurocrine Biosciences, INC. | $50.78 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $41.38 | 2019 | |
| Lundbeck LLC | $36.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.03 | 2019 | |
| Amgen INC. | $2.23 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.